614
Participants
Start Date
December 31, 2008
Primary Completion Date
December 31, 2015
Study Completion Date
November 30, 2016
Doxorubicin
Doxorubicin 60 mg/m2
Cyclophosphamide
Cyclophosphamide 600 mg/m2
Ixabepilone (Ixempra)
Ixabepilone 40 mg/m2
Paclitaxel (Taxol)
Paclitaxel 80 mg/m2
University of Pittsburgh Medical Center, Pittsburgh
Bux-Mont Oncology, Fox Chase Cancer Center, Rockledge
Center for Cancer and Blood Disorders, Bethesda
Weinberg Cancer Institute at Franklin Square, Baltimore
Virginia Cancer Institute, Richmond
Peninsula Cancer Institute, Newport News
Alamance Regional Medical Center, Burlington
South Carolina Oncology Associates, PA, Columbia
Spartanburg Regional Medical Center, Spartanburg
Medical University of South Carolina, Charleston
Lowcountry Hematology Oncology, Mt. Pleasant
Coastal Cancer Center, Myrtle Beach
Suburban Hem Onc, Lawrenceville
Piedmont Healthcare, Atlanta
Emory/Winship Cancer Institute, Atlanta
Northeast Georgia Medical Center, Gainesville
Augusta Oncology Associates, Augusta
Medical Oncology Associates of Augusta, Augusta
Medical College of Georgia Cancer Specialists, Augusta
Integrated Community Oncology Network, Jacksonville
Space Coast Medical Associates, Titusville
Memorial Regional Cancer Center, Hollywood
Aventura Medical Center, Aventura
Holy Cross Hospital, Fort Lauderdale
Florida Cancer Care, Davie
Lynn Cancer Institute, Boca Raton
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Cancer Center of Huntsville, Huntsville
Clearview Cancer Institute, Huntsville
Northeast Alabama Regional Medical Center, Anniston
University of Southern Alabama, Mobile
Tennessee Oncology, PLLC, Nashville
Associates in Hematology Oncology, Chattanooga
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Collierville
Consultants in Blood Disorders and Cancer, Louisville
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus
Hickman Cancer Center (Flower Hospital), Sylvania
Hematology/Oncology Inc, Elyria
Oncology Hematology Care, Cincinnati
Hematology Oncology of Indiana, Indianapolis
Oncology Hematology Associates of SW Indiana, Evansville
Providence Medical Group, Terre Haute
Grand Rapids Clinical Oncology Program, Grand Rapids
Fairview Medical Oncology Clinic, Edina
Hematology Oncology of the North Shore, Skokie
Mid-Illinois Hematology & Oncology, Normal
St. Louis Cancer Care, Chesterfield
Research Medical Center, Kansas City
St. John's Clinic, Springfield
Kansas City Cancer Centers, Overland Park
Cotton O'Neil Cancer Center, Topeka
Methodist Cancer Center, Omaha
Baton Rouge General Medical Center, Baton Rouge
Northeast Arkansas Clinic, Jonesboro
Center for Cancer and Blood Disorders, Fort Worth
Medical Oncology Methodist Hospital, Houston
South Texas Oncology and Hematology, San Antonio
Coastal Bend Cancer Center, Corpus Christi
New Mexico Oncology Hematology Consultants, Albuquerque
Wilshire Oncology Medical Group, La Verne
New Hope Cancer and Research Institute, Pomona
Eastern Connecticut Hematology Oncology, Norwich
Mercy Hospital, Portland
Fallon Clinic, Worcester
St. Clare's Hospital Oncology and Hematology, Denville
Hematology Oncology Associates of Northern NJ, Morristown
Southern Oncology and Hematology, Vineland
San Juan Hospital, San Juan
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
SCRI Development Innovations, LLC
OTHER